| Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity (NCT07662356) | Chinese University of Hong Kong | 2019-12-16 |
| Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis (NCT03572465) | Centre hospitalier de l'Université de Montréal (CHUM) | 2019-10-23 |
| Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease (NCT03836443) | Assistance Publique - Hôpitaux de Paris | 2019-02-14 |
| Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease (NCT03459079) | University of Florida | 2018-08-14 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (NCT03486899) | Bristol-Myers Squibb | 2018-06-19 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (NCT03486912) | Bristol-Myers Squibb | 2018-06-12 |
| Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes (NCT03525769) | Nanfang Hospital, Southern Medical University | 2018-05-05 |
| Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease (NCT02217345) | Massachusetts General Hospital | 2017-06-02 |
| Anti-LPS Antibody Treatment for Pediatric NAFLD (NCT03042767) | Miriam Vos, MD | 2017-02-01 |
| Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients (NCT04059029) | Taipei Medical University Hospital | 2016-10-01 |
| Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) (NCT02781584) | Gilead Sciences | 2016-06-13 |
| Tesamorelin Effects on Liver Fat and Histology in HIV (NCT02196831) | Massachusetts General Hospital | 2015-07-01 |
| Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD (NCT02244944) | Gregory Graf, PhD | 2014-09-01 |
| Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease (NCT02213224) | Nanfang Hospital, Southern Medical University | 2014-08-01 |
| Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease (NCT01930123) | Manal F Abdelmalek | 2013-10-01 |
| Multimodal Approach in IBD Patients (NCT01705522) | Clinical Hospital Colentina | 2012-10-01 |
| Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children (NCT01529268) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2012-06-01 |
| Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin (NCT01544751) | Prof Antonino Belfiore | 2011-09-01 |
| The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) (NCT01265498) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2011-03-01 |